ALL (Acute Lymphoblastic Leukemia) and AML (Acute Myeloid Leukemia) are both types of acute leukemia, a cancer that affects the production of blood cells in the bone marrow. While they are both aggressive malignancies, they have some distinct differences.
The two types of leukemia have different origins and involve different types of cells. ALL arises from the overproduction of immature lymphocytes, or white blood cells, in the bone marrow. AML is a malignancy of immature myeloid cells, which include red blood cells, platelets, and other white blood cells.
In terms of symptoms, they can both present with similar signs and symptoms, such as fatigue, anemia, fever, and bleeding. However, ALL can also present with swollen lymph nodes and an enlarged spleen or liver, whereas AML is more likely to lead to infections and/or bone pain.
The treatment of ALL and AML also differs. ALL is more likely to respond to chemotherapy and can be treated with a combination of medications. AML is usually treated with chemotherapy, but may also require a stem cell transplant.
Finally, the prognosis of ALL and AML also differs. ALL has a higher survival rate, with an overall 5-year survival rate of up to 90%. AML, on the other hand, has a lower overall survival rate, with a 5-year survival rate of only 40-60%.
In summary, ALL and AML are both types of acute leukemia, but they have distinct differences in terms of their origins, symptoms, treatments, and prognosis.